Aside from the development of small-molecule drugs that free p53 from inhibition by its negative regulators such as MDM2, immunotherapies that aim to improve the human immune system’s ability to recognize and eradicate cancer cells with deregulated p53 have sparked considerable interest in recent years. The gene discussed is TP53; the disease is cancer.